DNA methylation of PITX2 predicts poor survival in men with prostate cancer.
OBJECTIVE
We investigated if methylation of candidate genes can be useful for predicting prostate cancer (PCa) specific death.


METHODS
Methylation of PITX2, WNT5a, SPARC, EPB41L3 and TPM4 was investigated in a 1:2 case-control cohort comprising 45 men with cancer of Gleason score ≤ 7 who died (cases), and 90 men who were alive or died of other causes with survival time longer than the cases (controls). A univariate conditional logistic regression model was fitted by maximizing the likelihood of DNA methylation of each gene versus the primary end point.


RESULTS
A 10% increase in methylation of PITX2 was associated with PCa related death with OR 1.56 (95% CI: 1.17-2.08; p = 0.005).


CONCLUSIONS
Our study strengthens prior findings that PITX2 methylation is useful as a biomarker of poor outcome of PCa and in addition we also suggest that it may be particularly useful in men with low Gleason score.
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts & London School of Medicine, Queen Mary University of London, London, EC1M 6BQ, UK.
Nataša
N
Vasiljević
Amar S
AS
Ahmad
Paul D
PD
Carter
Gabrielle
G
Fisher
Daniel M
DM
Berney
Christopher S
CS
Foster
Jack
J
Cuzick
Attila T
AT
Lorincz
D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism*; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000378:metabolism*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D018398:Homeodomain Proteins / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D015996:Survival Rate; D014157:Transcription Factors / Q000378:metabolism*; D000097577:Homeobox Protein PITX2
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D018398:Homeodomain Proteins; D009363:Neoplasm Proteins; D014157:Transcription Factors; D000097577:Homeobox Protein PITX2
DNA methylation; PITX2; prognostic biomarker; prostate cancer